Synlogic Announces Proposed Public Offering of Common Stock

Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2018 Catalysts

Synlogic and Ginkgo Bioworks Announce Collaboration as First Step Toward Building an Unprecedented Discovery Engine for Novel Living Medicines in Neurological and Liver Disorders

Synlogic Reports Third Quarter 2017 Financial Results and Recent Progress

Synlogic to Present at Upcoming Investor Conferences in November

Synlogic Reports Positive Top-Line Phase 1 Data Demonstrating Safety and Tolerability and Proof of Mechanism in Healthy Volunteers for SYNB1020, a Synthetic BioticTM Medicine for the Treatment of Hyperammonemia

Synlogic Receives Orphan Drug Designation for SYNB1618, a Synthetic BioticTM Medicine for the Treatment of Phenylketonuria

Synlogic Strengthens Leadership Team with Appointment of Chief Operating Officer and Chief Human Resources Officer

Synlogic to Webcast Presentation at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

Synlogic Presents New Preclinical Data at International Congress of Inborn Errors of Metabolism

Synlogic to Webcast Presentation at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference

Synlogic Completes Merger with Mirna Therapeutics